EDIT - Editas Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617-401-9000
http://www.editasmedicine.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees133

Key Executives

NameTitlePayExercisedYear Born
Ms. Cynthia L. CollinsCEO, Pres & Director2.47kN/A1958
Dr. Vickesh MyerChief Technology Officer509.28k3.04M1967
Dr. Charles AlbrightChief Scientific Officer532.27k379.58k1958
Dr. Feng ZhangCo-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. George M. ChurchCo-Founder & Scientific Advisory Board MemberN/AN/A1954
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Editas Medicine, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.